Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | WX390 |
Synonyms | |
Therapy Description |
WX390 is a dual inhibitor of PI3K and mTOR, which may block downstream signaling and lead to tumor growth inhibition (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 3106-3106). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
WX390 | WXFL10030390|WXFL 10030390|WXFL-10030390|WX 390|WX-390 | mTOR Inhibitor 51 PI3K Inhibitor (Pan) 42 | WX390 is a dual inhibitor of PI3K and mTOR, which may block downstream signaling and lead to tumor growth inhibition (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 3106-3106). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA mutant | head and neck cancer | predicted - sensitive | WX390 | Case Reports/Case Series | Actionable | In a Phase I trial, WX390 treatment resulted in a partial responses in a patient with head and neck cancer harboring PIK3CA mutation, and stable disease with tumor shrinkage for 8 months in another patient with PIK3CA-mutant head and neck cancer (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 3106-3106; NCT03730142). | detail... |
PIK3CA mutant | cervical cancer | predicted - sensitive | WX390 | Case Reports/Case Series | Actionable | In a Phase I trial, WX390 treatment resulted in a partial responses in a patient with cervical cancer harboring PIK3CA mutation (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 3106-3106; NCT03730142). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|